The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December 2020 and mathematical models suggest that mRNA vaccines prevented at least 14.4 million deaths from COVID-19 in the first year alone.

Their extraordinary effectiveness in having softened the blow of the disease has led to the development of mRNA vaccines to also combat other infectious pathogens.

Clinical trials for influenza virus, Respiratory Syncytial Virus (RSV), HIV, Zika, Epstein-Barr virus, and tuberculosis bacteria are all on the way. Importantly, however, COVID-19 research has revealed shortcomings of mRNA vaccines that highlight the need for different approaches.